Pfizer has acquired the ability to realize extended cost savings that will gun its earnings over the next several years as the combined shop realizes a whopping $2.5 billion in savings by 2005.

The United States has been reluctant to purchase and distribute genericAIDS treatments,and this caution has been vindicated.

Companies do not want to be around governments that hate them, and nobody seems to loathe the drug industry more than New York's Washington delegation.

Regardless of the intentions, clinical drug trials driven primarily by marketing yield enormous benefits for patients and practitioners.

What happens asAIDS mutates and new drugs are needed to take the place of the ones that work currently?

The use of social criteria may be fine for affluent investorswho assume the extra risk to achieve their perceived political goals and the Gates Foundation has set a higher standard.

Ensuring that there are profits to be made from HIV/AIDS is probably the best way to keep companies investing and researching.

Should countries should be switching from existing therapies of brand-name drugs to formulations made from knockoff drugs that are simpler for patients to take?